ES2186870T3 - Complejo de factor viii estable, procedimiento para su preparacion asi como preparaciones farmaceuticas del mismo. - Google Patents

Complejo de factor viii estable, procedimiento para su preparacion asi como preparaciones farmaceuticas del mismo.

Info

Publication number
ES2186870T3
ES2186870T3 ES97906928T ES97906928T ES2186870T3 ES 2186870 T3 ES2186870 T3 ES 2186870T3 ES 97906928 T ES97906928 T ES 97906928T ES 97906928 T ES97906928 T ES 97906928T ES 2186870 T3 ES2186870 T3 ES 2186870T3
Authority
ES
Spain
Prior art keywords
well
procedure
preparation
same
pharmaceutical preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97906928T
Other languages
English (en)
Other versions
ES2186870T5 (es
Inventor
Bernhard Fischer
Artur Mitterer
Friedrich Dorner
Johann Eibl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter AG
Original Assignee
Baxter AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3492100&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2186870(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter AG filed Critical Baxter AG
Application granted granted Critical
Publication of ES2186870T3 publication Critical patent/ES2186870T3/es
Publication of ES2186870T5 publication Critical patent/ES2186870T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE DESCRIBE UN FACTOR ESTABLE DE COMPLEJO VIII/VWF QUE CONTIENE SOBRE TODO MULTIMEROS VWF DE ALTO PESO MOLECULAR Y ESTA LIBRE DE MOLECULAS VWF DE BAJO PESO MOLECULAR Y DE PRODUCTOS DE DESCOMPOSICION VWF PROTEOLITICOS. LA INVENCION TRATA ASIMISMO DE UN PROCEDIMIENTO PARA PREPARAR ESTOS COMPLEJOS.
ES97906928T 1996-03-15 1997-03-13 Complejo de factor viii estable, procedimiento para su preparacion asi como preparaciones farmaceuticas del mismo. Expired - Lifetime ES2186870T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT494/96 1996-03-15
AT0049496A AT403764B (de) 1996-03-15 1996-03-15 Stabiler faktor viii/vwf-komplex

Publications (2)

Publication Number Publication Date
ES2186870T3 true ES2186870T3 (es) 2003-05-16
ES2186870T5 ES2186870T5 (es) 2009-06-19

Family

ID=3492100

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97906928T Expired - Lifetime ES2186870T5 (es) 1996-03-15 1997-03-13 Complejo de factor viii estable, procedimiento para su preparacion asi como preparaciones farmaceuticas del mismo.

Country Status (10)

Country Link
US (3) US6228613B1 (es)
EP (1) EP0888386B2 (es)
JP (1) JP2000506869A (es)
AT (2) AT403764B (es)
CA (1) CA2248960C (es)
DE (1) DE59708667D1 (es)
DK (1) DK0888386T4 (es)
ES (1) ES2186870T5 (es)
PT (1) PT888386E (es)
WO (1) WO1997034930A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406867B (de) 1997-02-27 2000-10-25 Immuno Ag Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
AT406373B (de) † 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
AT408443B (de) * 1998-02-27 2001-11-26 Immuno Ag Verfahren zur gewinnung von gereinigtem faktor viii:c/vwf-komplex
US6605222B1 (en) * 1998-05-20 2003-08-12 Baxter Aktiengesellschaft Method for producing a factor VIII/von Willebrand factor complex
AT409335B (de) * 1998-11-10 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
ATE497171T1 (de) * 1999-07-05 2011-02-15 Leuven K U Res & Dev Von willebrand-faktor-aktivitätsnachweis
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
DE10246125A1 (de) * 2002-10-01 2004-04-15 Aventis Behring Gmbh Konzentrat eines Faktor VIII:C-haltigen von-Willebrand-Faktors und das dazu gehörige Verfahren
JP3830501B2 (ja) * 2003-01-17 2006-10-04 株式会社ティーティーシー アフィニティートラップリアクター、及びそれを用いたアンジオスタチン様断片のヒト血漿からの一段階精製プロセス
WO2005012354A1 (en) * 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
BRPI0514435B8 (pt) 2004-08-20 2021-05-25 American Nat Red Cross isolamento sequêncial de proteínas e esquemas de purificação através de cromatografia por afinidade
US7875288B2 (en) * 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
WO2007117469A2 (en) * 2006-03-30 2007-10-18 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
HUE035243T2 (hu) 2007-02-23 2018-05-02 Sk Chemicals Co Ltd Eljárás VIII. faktor és származékainak elõállítására és tisztítására
ITLU20070007A1 (it) * 2007-05-07 2008-11-08 Kedrion Spa Processo cromatografico per l'ottenimento di un complesso fviii/vwf con differenti rapporti tra le due proteine da utilizzare nella terapia della emofilia a e nella malattia di von willebrand.
HRP20110927T1 (hr) * 2007-12-28 2012-02-29 Baxter International Inc. Protutlačna filtracija proteina
PL2291523T3 (pl) * 2008-06-24 2015-05-29 Csl Behring Gmbh Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo
EP2349314B1 (en) * 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
GB0915480D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
SG191186A1 (en) 2010-12-15 2013-07-31 Baxter Int Eluate collection using conductivity gradient
DK3412305T3 (da) * 2011-06-10 2021-03-01 Baxalta GmbH Behandling af koagulationssygdom ved administration af rekombinant vwf
KR20140084208A (ko) 2011-10-18 2014-07-04 시에스엘 리미티드 정제된 인자 ｖｉｉｉ의 재구성 후의 안정성을 향상시키는 방법
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
SG11201903954WA (en) * 2016-11-11 2019-05-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
EP4424366A3 (en) 2017-07-07 2024-12-04 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
EA202192140A1 (ru) 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
WO2021001522A1 (en) * 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
WO2022218962A1 (en) * 2021-04-13 2022-10-20 Grifols Worldwide Operations Limited Liquid composition comprising factor viii or factor viii/von willebrand factor complex

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403473D0 (en) * 1984-02-09 1984-03-14 Special Trustees For St Thomas Purification of factor viii
US5149787A (en) † 1984-05-22 1992-09-22 The Blood Center Research Foundation Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
US4707441A (en) 1984-08-06 1987-11-17 Technicon Instruments Corp. Binding assays in automated apparatus with liposome compatible surfactants
FR2570276B1 (fr) 1984-09-18 1987-09-04 Immunotech Sa Procede d'obtention du complexe fviii/vwf a usage therapeutique et produits en resultant
US5250421A (en) * 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
JP2872255B2 (ja) 1987-01-30 1999-03-17 バイオジエン，インコーポレイティド ファクター▲ｖｉｉｉ▼の高収量生産法
FR2632309B1 (fr) 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
US5110907A (en) † 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
FR2651437A1 (fr) 1989-09-05 1991-03-08 Lille Transfusion Sanguine Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total.
JP2931655B2 (ja) 1990-09-12 1999-08-09 サントル・レジョナル・ド・トランスフユジョン・サンギン・ド・リール 全血漿から血液疑固▲ｖｉｉｉ▼因子―フオン・ビルブラント因子複合体濃縮物の製造方法
FR2673632A1 (fr) 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
DE4204694C3 (de) 1992-02-01 1995-10-12 Octapharma Ag Verfahren zur Gewinnung von hochreinem, virusinaktiviertem Faktor VIII mittels Anionenaustauscher-Chromatographie
AT399818B (de) 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
IT1256622B (it) * 1992-12-04 1995-12-12 Sclavo Spa Processo per l'estrazione del complesso fattore viii-fattore von willebrand (fviii:c-fvw) da plasma umano totale.
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
US6005077A (en) 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
DE19616540A1 (de) 1995-11-10 1997-05-15 Immuno Ag Verwendung von von Willebrand-Faktor und pharmazeutische Zubereitung
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
GB0225903D0 (en) 2002-11-07 2002-12-11 Siemens Ag Method for uplink access transmissions in a radio communication system

Also Published As

Publication number Publication date
ES2186870T5 (es) 2009-06-19
ATA49496A (de) 1997-10-15
AT403764B (de) 1998-05-25
US20050209154A1 (en) 2005-09-22
DK0888386T4 (da) 2009-05-11
JP2000506869A (ja) 2000-06-06
CA2248960A1 (en) 1997-09-25
US7498146B2 (en) 2009-03-03
EP0888386A1 (de) 1999-01-07
DE59708667D1 (de) 2002-12-12
EP0888386B2 (de) 2009-04-01
ATE227310T1 (de) 2002-11-15
WO1997034930A1 (de) 1997-09-25
US6228613B1 (en) 2001-05-08
EP0888386B1 (de) 2002-11-06
US20020025556A1 (en) 2002-02-28
US6924151B2 (en) 2005-08-02
CA2248960C (en) 2009-12-15
DK0888386T3 (da) 2003-02-17
PT888386E (pt) 2003-03-31

Similar Documents

Publication Publication Date Title
ES2186870T3 (es) Complejo de factor viii estable, procedimiento para su preparacion asi como preparaciones farmaceuticas del mismo.
NO970210L (no) Heteroatomholdige cyklopentanopyridyl-oksazolidinoner
PT1036059E (pt) Derivados de adamantano
NO20002785L (no) Adamantanderivater
PY950041A (es) Compuesto de 1- fenil 3-dimetilamino- propano a procedimientos para su preparacion y a la aplicacion de estas sustancias en farmacologia
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
NO963462L (no) Paramunitetinducer basert på kombinasjoner av poxvirus komponenter, fremgangsmåte for fremstilling derav og anvendelse som medikament
HN1996000017A (es) Isotiazolonas
ATE265468T1 (de) Sprühgetrocknetes erythropoietin
SV1995000062A (es) DERIVADOS DE CICLOALCANO-INDOL Y - AZAINDOL REF. Le A 30 699
HUP9903106A3 (en) 7alpha-(zeta-aminoalkyl)estratrienes, process for preparing the same, pharmaceutical preparations containing said 7alpha(zeta-aminoalkyl)estratrienes and their use for preparing medicaments
ATE210988T1 (de) Zytotoxischer aminozucker und verwandte zuckerderivate von indolopyrrolocarbazolen
MX9702666A (es) Nuevos peptidos con efectos inmunoreguladores.
DK0952853T3 (da) Konjugat omfattende et aktivt middel, et polypeptid og en polyether
DE69324601D1 (de) Multifunktionelle neurotrophe faktoren
DE3767977D1 (de) Lacton-abbauprodukt, verfahren zu dessen herstellung und dessen verwendung.
IT8026672A0 (it) Derivati peptidici, procedimento per prepararli e relative composizioni farmaceutiche.
NO20021573L (no) Tverrbundne kopolymerer basert på ikke-tverrbundne polykarboksyl-kopolymerer
ES2187557T3 (es) Utilizacion de dextrano sustituido para el tratamiento de las lesiones del sistema nervioso y fracciones enriquecidas en heparano sulfato.
ES2129053T3 (es) Nuevos derivados de fosfolipidos.
DE59107762D1 (de) Komplexe, enthaltend S(+)-Phenyl-alkansäuren und alpha-Hydroxy-alkansäuren
MX9206365A (es) Tetrahidrobenzotienopiridinas,proceso para su preparacion y composicion farmaceutica que las contiene
ECSP951481A (es) Compuestos de 1-fenil-3- dimetilamino propano con efecto farmacologico
MX9706395A (es) Particulas de celulosa, metodo para producirlas, y su uso.
GR1001635B (el) Μέ?οδος παρασκευής 3-[2-(διμε?υλαμινο)-αι?υλο]-ν-με?υλο-1η-ινδόλης-5-με?ανοσουλφοναμίδης.